Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030353 | 0.82 | LMNA (0.48) | LMNATSHRUSP2MAPK1SMN1; SMN2 | |
| SCHEMBL16900285 | 0.81 | USP2 (0.62) | LMNATSHRUSP2MAPK1SMN1; SMN2 | |
| SCHEMBL20110258 | 0.76 | MAPK1 (0.43) | LMNAMAPK1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL18136489 | 0.75 | SMN1; SMN2 (0.46) | LMNATSHRMAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL6031290 | 0.72 | KDM4E (0.49) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11582679 | 0.72 | SMN1; SMN2 (0.52) | LMNATSHRMAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL11510201 | 0.72 | MAPK1 (0.43) | LMNAMAPK1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL236974 | 0.72 | KDM4A (0.45) | LMNATSHRUSP2MAPK1SMN1; SMN2 | |
| SCHEMBL2832928 | 0.71 | MAPK1 (0.47) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL14007393 | 0.70 | NPC1 (0.52) | SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | LMNA 2176/4885TSHR 4191/4885USP2 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.